<DOC>
	<DOCNO>NCT03098823</DOCNO>
	<brief_summary>To compare effect RAYOS® versus immediate-release ( IR ) prednisone fatigue measure Functional Assessment Chronic Illness Therapy-Fatigue ( FACIT-F ) .</brief_summary>
	<brief_title>A Crossover Study Compare RAYOS IR Prednisone Improve Fatigue Morning Symptoms SLE</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Provide write informed consent agree study procedure , studyspecific procedure do . 2 . Males nonpregnant female , age 18 year old 3 . Diagnosis SLE either American College Rheumatology ( ACR ) Systemic Lupus International Collaborating Clinics Classification ( SLICC ) criteria 4 . Fatigue measure FACITF ≤30 . 5 . On stable regimen IR prednisone ( 5 15 mg/day ) period least 30 day prior Screening , expect remain stable next 6 month . 6 . On stable SLE treatment regimen period least 30 day prior Screening , expect remain stable next 6 month . Any following medication permit stable least 30 day prior Screening expect remain stable next 6 month : Hydroxychloroquine equivalent antimalarial Other immunosuppressive immunomodulatory agent include methotrexate , azathioprine , leflunomide , mycophenolate ( include mycophenolate sodium mycophenylate mofetil 2 grams/day ) , belimumab , cyclophosphamide , calcineurin inhibitor ( e.g . tacrolimus , cyclosporine ) 7 . Entry daily ePRO data 11 14 day baseline period , completion least 6 8 weekly ePRO questionnaire baseline period 8 . Willing able perform comply study procedure , include take pill daily prescribe , complete ePROs smart phone , wear smart watch day night , bring smartphone activity away home ( e.g. , walk , errand , visit , shopping , travel ) , keep smartphone smartwatch charge daily , carefully use smartphone smartwatch clinical tool keep secure others , attend monthly clinic visit schedule 9 . Females childbearing potential must currently use highly effective method contraception may include , limited , abstinence , sex person sex , monogamous relationship vasectomize partner , hysterectomy , bilateral tubal ligation , license hormonal method , intrauterine device , use spermicide combine barrier method ( e.g. , condom , diaphragm ) 30 day 90 day receive study drug 1 . Previously take follow medication : RAYOS® Rituximab within 6 month prior Screening Any investigational therapy within 3 month 5 halflives agent prior Screening 2 . History noncompliance take pill prescribe . 3 . Rapidly progressive neurologic disease 4 . Rapidly progressive renal disease ( define proteinuria &gt; 6 g/24 hour equivalent use spot urine protein creatinine ratio , serum creatinine &gt; 2.5 mg/dL ) 5 . Diagnosis fibromyalgia 6 . Any following clinical laboratory abnormality : Hemoglobin &lt; 8.0 mg/dL Platelet count &lt; 50,000/mm3 White blood count ( WBC ) ≤ 2000/mm3 ; may 19991000/mm3 stable related SLE Absolute neutrophil count ( ANC ) ≤1000/mm3 ; may 500999/mm3 stable related SLE Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≥3× upper limit normal ( ULN ) unless relate SLE Calculated creatinine clearance ≤25 mL/min per 1.73 m2 ( CockcroftGault equation ) 7 . Grade 3 great laboratory abnormality base National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE ; Appendix 3 ) except follow allow : Activated partial thromboplastin time ( PTT ) &gt; &gt; 2.5× ULN due lupus anticoagulant relate liver disease anticoagulant therapy Hypoalbuminemia &lt; 2 g/dL due chronic lupus nephritis , relate liver disease Gamma glutamyl transferase ( GGT ) &lt; 20× ULN due lupus hepatitis , relate alcoholic liver disease , uncontrolled diabetes , viral hepatitis . If present , abnormality ALT and/or AST must ≤5× ULN 8 . Pregnant nursing , females use effective contraception 9 . Current drug alcohol abuse dependence , history drug alcohol abuse dependence within 1 year prior Screening 10 . Clinical evidence significant unstable uncontrolled acute chronic disease cause SLE ( e.g. , diabetes , cardiovascular , pulmonary , hematologic , gastrointestinal , neurological , infectious ) , opinion Investigator , could confound result study put subject undue risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>